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Abstract: The concept is emerging that low-normal thyroid function, i.e., either higher 
thyroid-stimulating hormone or lower free thyroxine levels within the euthyroid reference 
range, could contribute to the development of atherosclerotic cardiovascular disease. It is 
possible that adverse effects of low-normal thyroid function on cardiovascular outcome may 
be particularly relevant for specific populations, such as younger people and subjects with 
high cardiovascular risk. Low-normal thyroid function probably relates to modest increases 
in plasma total cholesterol, low density lipoprotein cholesterol, triglycerides and insulin 
resistance, but effects on high density lipoprotein (HDL) cholesterol and non-alcoholic fatty 
liver disease are inconsistent. Low-normal thyroid function may enhance plasma cholesteryl 
ester transfer, and contribute to an impaired ability of HDL to inhibit oxidative modification 
of LDL, reflecting pro-atherogenic alterations in lipoprotein metabolism and HDL function, 
respectively. Low-normal thyroid function also confers lower levels of bilirubin, a strong 
natural anti-oxidant. Remarkably, all these effects of low-normal thyroid functional status 
appear to be more outspoken in the context of chronic hyperglycemia and/or insulin 
resistance. Collectively, these data support the concept that low-normal thyroid function may 
adversely affect several processes which conceivably contribute to the pathogenesis of 
atherosclerotic cardiovascular disease, beyond effects on conventional lipoprotein measures. 
Keywords: bilirubin; biomarkers, cardiovascular disease; cholesteryl ester transfer; 
dyslipidemia; lipids; metabolic syndrome; non-alcoholic fatty liver disease; subclinical 
hypothyroidism; thyroid hormones  
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1. Introduction 
It is widely appreciated that overt hypothyroidism adversely affects cardiovascular morbidity and 
mortality [1,2]. However, it has not been unequivocally established whether subclinical hypothyroidism 
(SCH) also contributes to the development of atherosclerotic cardiovascular disease (CVD) [3]. The 
prevalence of overt hypothyroidism varies from 0.1% to 3.7% [4–6]. SCH, defined as a plasma thyroid-
stimulating hormone (TSH) level above the institutional reference range (in most laboratories >  
4.0−4.5 mU·L−1) combined with a plasma free thyroxine (FT4) or free triiodothyronine (FT3) level 
within the reference range [3], is more common, ranging between 4.6% and 8.5% in the general 
population, even rising to 15% in elderly populations [5,6].  
The high prevalence of thyroid dysfunction has considerable consequences for a several important 
health issues, including cardiometabolic disorders [7]. Since each individual probably has a narrow  
set-point of thyroid function status [8], the concept is now emerging that low-normal thyroid, i.e., higher 
TSH and/or lower free thyroid hormone levels within the euthyroid reference range, even when 
determined at a single time-point, could have a negative impact on atherosclerotic cardiovascular  
disease [7,9]. Of interest is a recent systematic review comprising observational studies, which has 
suggested an increased risk of higher plasma total cholesterol, low density lipoprotein (LDL) cholesterol 
and triglycerides, as well as obesity, metabolic syndrome and chronic kidney disease in the context of 
low-normal thyroid function [7]. 
This review is focused on recent data with respect to the effect of low-normal thyroid function on 
(surrogate markers of) cardiovascular outcome, as well as on novel lipid and non-lipid biomarkers which 
are conceivably involved in the pathogenesis of atherosclerotic CVD.  
1.1. Subclinical Hypothyroidism, Low-Normal Thyroid Function and Atherosclerotic  
Cardiovascular Disease 
The extent to which subclinical hypothyroidism is causally implicated in accelerated development of 
atherosclerosis has not been unequivocally established. A considerable number of cross-sectional and 
prospective studies on the association between SCH and cardiovascular disease have been reported 
during the past two decades [3,10–15]. In an early report from the Rotterdam cohort, an elevated age-adjusted 
prevalence of aortic atherosclerosis and myocardial infarction was documented among 1149 postmenopausal 
women [10]. These associations remained significant after an additional adjustment for the body mass 
index (BMI), total cholesterol and high density lipoprotein (HDL) cholesterol, blood pressure and 
smoking status, and were slightly stronger in women who also had antibodies to thyroid peroxidase. In 
this cross-sectional study, the population attributable risk of SCH for myocardial infarction was as large 
as that of established cardiovascular risk factors [10]. On the other hand, in a community-dwelling 
population study from the USA, comprising 3233 subjects, SCH did not independently predict 
cardiovascular morbidity and mortality during a follow-up period of about 12 years [11]. Remarkably, a 
large retrospective study from Denmark, which included more than 500,000 subjects, recently 
demonstrated a modest reduction in all-cause mortality associated with SCH during 5.5 years of follow-up 
(hazard ratio, 0.92) [12]. The association of a lower all-cause mortality with SCH was observed only in 
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subjects aged > 65 years. In that report, the occurrence of major adverse cardiovascular events was 
unrelated to SCH [12]. 
Three meta-analyses have been published, which aimed at assessing the strength of the association 
between SCH and CVD. Ochs et al. reported that SCH is associated with a non-significant 20% higher 
relative risk for cardiovascular disease in a meta-analysis involving a total of 14,449 participants [13]. 
In secondary analysis, cardiovascular mortality risk appeared to be greater in those studies in which 
mean age of study participants was <65 years compared to studies in which mean age was ≥65 years 
(relative risk, 1.50 vs. 1.20) [13]. Razvi et al. observed a modestly increased prevalence of ischemic 
heart disease attributable to SCH (odds ratio, 1.23; 27,267 subjects); the incidence of CVD associated 
with SCH was not significant (odds ratio, 1.27; 9627 subjects) [14]. In line with the first meta-analysis, 
they reported an increased prevalence and incidence of ischemic heart disease in conjunction with SCH 
in studies including subjects <65 years of age (odds ratio, 1.57 and 1.68, respectively), but not in studies 
which only included subjects ≥65 years of age (odds ratios, 1.01 and 1.02, respectively) [14]. A similar 
age-dependent trend was found for cardiovascular mortality [14]. A third meta-analysis by Singh et al. 
documented that SCH confers an increased relative risk of both prevalent coronary heart disease (relative 
risk, 1.53; 11,495 subjects), and incident coronary heart disease (CHD) (relative risk, 1.19; 7026  
subjects [15]. They also observed an elevated risk of cardiovascular death among SCH subjects (relative 
risk, 1.28), although not significantly so in all-cause mortality (relative risk, 1.35) [15]. Collectively, several 
reports have thus suggested that the association of SCH with higher risk of CVD may be age-dependent, 
without any excess risk or perhaps even protection in elderly subjects [3,12–14]. Given the observational 
nature of these studies, it should be noted that neither the possibility of residual bias, nor that of reverse 
causation, can be fully excluded.  
Carotid intima–media thickness (cIMT), measured by ultrasound, is a predictor of coronary heart 
disease and stroke, and represents an established surrogate marker of subclinical atherosclerosis [16–18]. 
cIMT has been found to be greater in subjects with overt hypothyroidism compared to euthyroid subjects, 
and may decrease after levothyroxine replacement [19]. In marked contrast, a German study that 
included subjects older than 45 years across the range from hypothyroidism to hyperthyroidism showed 
that cIMT was lower in the context of higher TSH levels [20]. In another cross-sectional study, no 
significant relation of cIMT with TSH was found after adjustment for conventional cardiovascular risk 
factors [21]. However, in a meta-analysis of observational studies including 3602 participants, Gao et al. 
recently demonstrated that SCH is associated with increased cIMT, particularly in the context of TSH 
levels > 10 mU·L−1 [22]. This report showed that SCH is associated with higher systolic blood pressure, 
higher plasma total cholesterol, low density lipoprotein (LDL) cholesterol and triglycerides [22]. It 
remains to be established in how far greater cIMT in SCH is attributable to these cardiovascular risk 
factors. Nonetheless, this meta-analysis is in agreement with the supposition that SCH may confer 
increased risk of subclinical atherosclerosis. In addition, SCH was found to be associated with 
subclinical atherosclerosis, using coronary artery calcification as marker of subclinical atherosclerosis, 
but only in subjects with concomitant non-alcoholic fatty liver disease (NAFLD) [23]. 
At present, less information is available about the association o low-normal thyroid function with 
cardiovascular outcome. The Hunt Study prospectively examined the association of CHD mortality with 
TSH levels within the reference range in a Norwegian population-based cohort study including 25,313 
men and women without known thyroid disease, cardiovascular disorders or diabetes mellitus at  
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baseline [24]. In this study, women with higher TSH levels within the normal range were positively and 
linearly associated with mortality from CHD (hazard ratio upper vs. lower tertile, 1.69). This association 
remained significant after adjustment for conventional cardiovascular risk factors, and was also only 
present in non-smokers. In non-smoking men, there was a positive but non-significant association of 
CHD mortality with TSH levels within the reference range. These important findings suggest that low-
normal thyroid function, as assessed by a high-normal TSH level, may increase the risk of CVD [24]. 
On the other hand, in another prospective study from the UK, 1191 individuals did not show a significant 
relationship between (cardiovascular) mortality and variation in TSH levels within the reference range, 
but it should be taken into consideration that this survey was primarily focused on subclinical 
hyperthyroidism [25]. 
Several studies have appeared during the past few years which were specifically aimed at evaluating 
whether cIMT is also influenced by low-normal thyroid function. In a cross-sectional study including 78 
Caucasian non-smoking, middle-aged, strictly euthyroid subjects, cIMT was found to be inversely 
related FT4, independent of plasma lipids and BMI [26]. In agreement, cIMT was associated inversely 
with FT4 among 643 euthyroid Japanese subjects [27]. However, cIMT was found to be unrelated to 
thyroid function parameters among middle-aged women, despite a positive association of TSH with 
pulse wave velocity [28]. Altogether, these results would agree with the hypothesis that low-normal 
thyroid function may promote the development of atherosclerosis. Clearly, large-scale prospective 
studies both with incident cardiovascular events and with cIMT changes over time as outcome are 
required to more definitely test whether variations in thyroid function within the normal range indeed 
confer increased cardiovascular risk. 
1.2. Changes in Plasma Lipoproteins and C-Reactive Protein Consequent to Subclinical 
Hypothyroidism and Low-Normal Thyroid Function 
The effects of SCH on plasma lipoprotein levels have been examined in a considerable number of 
studies, as reviewed elsewhere [29–33]. In summary, SCH is likely to result in modest increases in 
plasma total cholesterol, LDL cholesterol, triglycerides and apolipoprotein (apo) B levels (Table 1). In 
SCH, these lipoprotein abnormalities may at least in part be normalized after levothyroxine treatment 
(Table 1). Minor and inconsistent changes in HDL cholesterol and in apoA-I, its most abundant 
apolipoprotein, have been reported in SCH [33]. Thus, taking into account that HDL cholesterol may be 
considerably elevated in overt hypothyroidism [30,33,34], it is remarkable that there are only minor 
elevations or even lower HDL cholesterol levels in conjunction with SCH. In addition, plasma levels of 
lipoprotein (a) (Lp(a)), a pro-atherogenic subfraction of LDL that is formed by disulfide bridges between 
apoB and apo(a), is probably unchanged in SHC [33], despite robust increases in overt hypothyroidism [35]. 
The effect of low-normal thyroid function on plasma (apo)lipoproteins has been evaluated by several 
studies so far. Nine larger studies (each comprising > 500 individuals; 90,041 subjects in total) have been 
reported in which the relationship of lipoprotein variables with high-normal TSH, low-normal FT4 and/or 
low-normal FT3 levels was determined [24,27,36−42]. As shown in Table 2, a positive relationship of 
plasma total cholesterol, LDL cholesterol and triglycerides was found in 3,1 and 3 of these reports, 
respectively. Four studies did not show a significant relationship of plasma total cholesterol and LDL 
cholesterol with TSH, whereas in two studies the relationship with triglycerides was not significant. The 
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relationship of these lipoprotein measures with FT4 was assessed in four studies. Plasma total cholesterol 
and LDL cholesterol were positively related to FT4 in one study but inversely in another report. Higher 
plasma triglycerides were related to lower FT4 levels in two studies and to higher FT4 in one paper. 
Variable effects of low-normal thyroid function on HDL cholesterol were demonstrated. In all these 
reports, the relationship of lipoprotein measures with TSH and/or FT4 were rather low (correlation 
coefficients < 0.12). Taken together, these studies suggests that low-normal thyroid function may give rise 
to small increases in plasma levels of apoB-containing lipoproteins, in keeping with qualitatively 
comparable lipoprotein alterations in SCH.  
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Table 1. Effects of overt and subclinical hypothyroidism on plasma (apo) lipoproteins, and of levothyroxine treatment in subclinical hypothyroidism. 
 Overt hypothyroidism Subclinical hypothyroidism Levothyroxine treatment  
Total cholesterol  ↑ ↑, ns ↓, ns 
LDL cholesterol  ↑ ↑, ns ↓, ns 
HDL cholesterol ↑ ↓, ns ↑,ns 
Triglycerides  ↑ ↑, ns ↓, ns  
Apolipoprotein B ↑ ↑ ↓ 
Apolipoprotein A-I ↑ ns ns 
Lp(a) ↑ ns ns 
HDL: high density lipoproteins; LDL: low density lipoproteins; Lp(a): lipoprotein (a). ↑: increased; ↓: decreased; ns: no significant effect. 
Table 2. Relationships of plasma (apo) lipoproteins with thyroid function parameters in euthyroid subjects as determined by cross-sectional 
analyses in population-based studies (all studies included > 500 individuals).  
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Table 2. Cont. 
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TSH: ns TSH: ns TSH: ns TSH: ns   
Wang [42]; 
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BMI: body mass index; FT4: free thyroxine; FT3: free triiodothyronine; TSH: thyroid-stimulating hormone; ns: not significant;  
Positive (+) and negative (-) associations are indicated. 
 
Nutrients 2015, 7 1359 
 
As reviewed elsewhere, inconsistent associations between SCH and enhanced low-grade chronic 
inflammation, most commonly assessed by high sensitive C-reactive protein (hsCRP) levels, have been 
reported so far [3]. In addition, besides a lack of difference in hsCRP, there was no difference in 
homocysteine levels between SCH and euthyroid subjects in the National Health and Nutrition 
Examination Survey [43]. Moreover, there was no association of hsCRP with low-normal thyroid 
function in two reports on the association of cIMT with low-normal thyroid function [26,27]. Thus, it 
seems unlikely that low-normal thyroid function has a major influence on low-grade chronic inflammation. 
2. Regulation of Lipid Homeostasis and Lipoprotein Metabolism by Thyroid Hormones  
Thyroid hormones have multifaceted and crucial roles in intracellular lipid homeostasis, as well as in 
plasma lipoprotein metabolism [30,31,33,44].  
2.1. Cholesterol Homeostasis 
Thyroid hormones induce the expression of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) 
reductase, a key regulator of cholesterol synthesis, which is able to convert HMG-CoA to mevalonate [45]. 
LDL receptor expression is also stimulated by thyroid hormones. The LDL receptor gene and one of its 
main regulatory factors, sterol regulatory element-binding protein-2 (SREBP-2), contain a thyroid 
hormone responsive element [46,47]. Consequently, LDL clearance is increased by the action of thyroid 
hormones. This results in lower plasma LDL cholesterol in hyperthyroidism and higher levels in 
hypothyroidism, despite stimulating effects of thyroid hormone on hepatic cholesterol synthesis [30,31,33]. 
During the past few years it has become increasingly clear that the proprotein converstase subtilisn-kexin 
type 9 (PCSK9) pathway is intricately involved LDL metabolism [48,49]. PCSK9 is a secreted protease 
that binds to the extracellular domain of the LDL receptor, thereby targeting it for lysosomal degradation 
after endocytosis. PCSK9 thus prevents LDL receptor recycling to the cell surface, impairing LDL 
receptor abundancy. Plasma PCSK9 levels are likely to be physiologically relevant, because LDL 
clearance is decreased at higher PCSK9 plasma levels [50]. Remarkably, PCSK9 expression is also 
regulated by SREBP-2 [48,49], again indicating the crucial role of this transcriptional factor in cellular 
cholesterol homeostasis. Against this background we recently determined whether low-normal thyroid 
function, as indicated by high-normal TSH levels, may confer increased PCSK9 plasma levels [51]. In 
non-obese subjects, plasma PCSK9 concentrations were related positively with TSH levels within the 
euthyroid range [51]. This finding raises the possibility that thyroid function status is a determinant of 
cellular cholesterol trafficking by affecting LDL receptor expression via PCSK9 regulation. However, 
whether the plasma concentration of PCSK9 is a useful marker of incident CVD awaits further study [52]. 
Of further note, while it is generally believed that effects of thyroid function status are exerted through 
intracellular actions of thyroid hormones, there is also recent evidence which suggests that TSH could have 
a direct effect on HMG-CoA expression [53]. Finally, biliary excretion of cholesterol and neutral steroids is 
decreased, whereas intestinal cholesterol absorption is increased in hypothyroidism [54].  
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2.2. Triglyceride Homeostasis 
Thyroid hormones have the ability to increase the mobilization of stored triglycerides by stimulating 
adipose tissue lipolysis [55], although there remain areas of uncertainty regarding the interplay between 
insulin action and adipose tissue lipolysis in hypothyroidism [56]. Circulating free fatty acid and glycerol 
levels are increased in hyperthyroidism [57,58], which results in an increased delivery of free fatty acids 
to the liver for subsequent re-esterification to triglycerides [55]. Notably, thyroid hormones concurrently 
stimulate hepatic fatty acid β-oxidation as well [55]. As a result of these divergent actions, hypothyroidism 
most likely results in enhanced hepatic triglyceride accumulation [9,59,60]. Hepatic fat accumulation is 
considered to represent a main driving force responsible for increased production of large very-low-density 
lipoprotein (VLDL) particles in the metabolic syndrome (MetS), as well as in Type 2 diabetes mellitus 
(T2DM) [61–63]. Furthermore, it should be noted that the clearance of VLDL particles in the circulation 
is decreased in hypothyroidism, due to impaired activity of lipoprotein lipase, resulting in decreased 
lipolysis of VLDL-derived triglycerides [57,58], and probably also to diminished hepatic VLDL removal 
via LDL receptor-related protein 1 [64]. Against this background, we set out to determine the relationship of 
VLDL subfractions with low-normal thyroid function. In a mixed group of euthyroid T2DM and  
non-diabetic subjects, lower FT4 levels were found to predict increased an concentration of large VLDL 
particles and a greater VLDL size independent of the presence of T2DM [65]. This finding is consistent 
with the hypothesis that abnormalities in triglyceride metabolism may represent an early event in the 
setting of low-normal thyroid function. 
2.3. Plasma lipoprotein metabolism 
The pathophysiological mechanisms responsible for increased plasma levels of LDL cholesterol and 
triglycerides in overt hypothyroidism, and opposite changes in overt hyperthyroidism have been detailed 
in the previous section [30,31,33]. Thyroid hormones also affect Lp(a) regulation [30,31,33,35,66]. The 
responsible mechanisms are not precisely known but probably involve LDL receptor-mediated clearance, 
as indirectly supported by recent observations which show that Lp(a) is dose-dependently decreased in 
response to administration of PCSK9 inhibiting monoclonal antibodies [67]. 
Thyroid hormones are prominently involved in the regulation of a number of other factors that play 
crucial roles in HDL metabolism, i.e., lecithin:cholesterol acyltransferase (LCAT), cholesteryl ester 
transfer protein (CETP), and hepatic lipase [30,31,33,35,68,69]. The HDL-associated enzyme, LCAT, 
is able to esterify free cholesterol to cholesteryl esters, thereby enhancing the conversion of lipid-poor 
pre β-HDL particles to larger, spherical HDL particles [70]. Subsequently, HDL-derived cholesteryl 
esters are transferred to triglyceride-rich lipoproteins by the action of CETP. As a consequence of this CETP-
mediated cholesteryl ester transfer (CET) process, the cholesterol content of HDL is decreased [70–72]. 
During the CET process triglycerides are transferred in the opposite direction from triglyceride-rich 
lipoproteins to HDL, resulting in triglyceride-enriched HDL particles. Triglycerides in these HDL 
particles are then hydrolyzed by hepatic lipase giving rise to smaller-sized HDL particles [70,71]. By a 
comparable mechanism, the CET process also contributes to the generation of atherogenic small-dense 
LDL particles. The plasma activities of LCAT, CETP and hepatic lipase are all increased by thyroid 
hormones [34,68,69,73]. Alterations in these factors act in concert to increase HDL cholesterol and  
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HDL size in the context of severe hypothyroidism, with opposite HDL changes in overt  
hyperthyroidism [30,31,33,73].  
2.4. Novel Lipid Biomarkers and Low-Normal Thyroid Function 
It is beyond doubt that low plasma levels of HDL cholesterol predict the future development of  
CVD [74,75], but the validity of the concept that raising HDL cholesterol as such provides a meaningful 
approach to reduce CVD risk has been seriously challenged during the past few years [76–78].  
As outlined above, the CET process contributes to an unfavorable plasma lipoprotein profile by 
lowering cholesterol content in HDL particles, raising the cholesterol content in triglyceride-rich 
lipoproteins, and providing a pathway responsible for the generation of small dense LDL particles. 
Remarkably, plasma CETP mass or activity levels per se are unlikely to predict incident CVD [79–81]. 
On the other hand, plasma CET, assayed by an isotope method that reflects CETP-mediated transfer of 
cholesteryl esters from endogenous HDL to VLDL and LDL, associates with increased cIMT [82], 
prospectively predicts CVD, even independent of plasma CETP mass and lipoprotein concentrations [83], 
and relates to younger age at presentation of myocardial infarction [84]. In view of the potential 
relevance of plasma CET for the development of atherosclerosis, and considering that plasma CET is 
elevated in T2DM in conjunction with high triglycerides [70,82], we have recently evaluated whether 
plasma CET is enhanced in the context of low-normal thyroid function. In a study comprising euthyroid 
subjects with and without T2DM, it was documented that plasma CET is positively related to high-normal 
TSH levels in T2DM subjects, but not in non-diabetic individuals [85]. It was, furthermore, shown that 
plasma CET was modified in the context of chronic hyperglycemia, as evidenced by a positive 
interaction of TSH with the presence of T2DM, or alternatively with fasting plasma glucose and the 
glycated hemoglobin level on plasma CET. Additionally, the positive relationship of plasma CET with 
triglycerides in T2DM subjects was more outspoken with higher TSH levels [85]. Collectively, these 
data underscore the concept that low-normal thyroid function may adversely influence a pro-atherogenic 
lipid biomarker in conjunction with chronic hyperglycemia and hypertriglyceridemia. From these results it 
seems conceivable that strict control of thyroid function status, as guided by a TSH level in the low-normal 
range, could be advantageous in T2DM patients who require levothyroxine substitution therapy. 
The relevance of HDL functional properties for cardioprotection has been recently emphasized [86,87]. 
In agreement with the contention that HDL may become dysfunctional, it was shown that cardiovascular 
risk is increased in subjects with concurrently high levels of HDL cholesterol and C-reactive protein [88]. 
Moreover, HDL’s anti-inflammatory function is diminished in acute myocardial infarction [89], and may 
predict recurrent coronary events, even independent from HDL cholesterol and plasma apoA-I [90]. 
Besides other potentially relevant athero-protective functions, HDL inhibits LDL from oxidative 
modification, thereby protecting against oxidative stress [87,89,91]. Importantly, it was demonstrated 
previously that LDL oxidizability is increased in overt hypothyroidism [92,93]. Additionally, oxidative 
stress markers are elevated in SCH [94,95], whereas high-normal TSH levels within the euthyroid range 
associate with elevations in oxidized LDL levels [96]. Oxidative stress is known to be enhanced in 
T2DM [81,97,98]. We, therefore, tested the extent to which low-normal thyroid function impacts on the 
ability of HDL to inhibit LDL oxidation in euthyroid subjects with varying degrees of glucose 
intolerance [90]. In this study, we used inhibition of HDL (standardized for the amount of HDL 
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cholesterol) on 2,2′-azobis (2-methylproprionamidine) dihydrochloride (AAPH)-induced formation of 
thiobarbituric acid reactive substances (TBARS) as read-out. It was found that an impaired HDL  
anti-oxidative capacity was determined by low-normal FT4 levels in T2DM subjects, but not in subjects with 
normal fasting plasma glucose [99]. We also showed that the relationship of FT4 with HDL anti-oxidative 
capacity varied according to glucose tolerance status. These findings agree with the concept that  
low-normal thyroid function may negatively impact on in this metric of HDL function under 
circumstances of chronic hyperglycemia. Thus, it appears that T2DM subjects may be particularly 
susceptible to low-normal thyroid function-related adverse effects on several lipid biomarkers which 
conceivably play a role in the pathogenesis of atherosclerotic CVD.  
3. Subclinical Hypothyroidism, Low-Normal Thyroid Function and Metabolic Syndrome  
The metabolic syndrome (MetS), commonly defined according to the NCEP-ATPIII criteria, is a 
cluster of metabolic disorders which include central obesity, elevated plasma glucose, high triglycerides, 
low HDL cholesterol and hypertension [100,101].  
The association of the presence of MetS with low-normal thyroid function has been documented in a 
number of epidemiological surveys [36–39,102]. In a cross-sectional analysis involving non-diabetic 
subjects participating in the PREVEND (Prevention of Renal and Vascular End stage Disease) study, 
low-normal thyroid function was predictive of 4 of the 5 MetS components; only blood pressure was 
unrelated to TSH and FT4 [34]. A high-normal TSH level also determined an increased prevalence of 
MetS in the Healthy ABC study, but did not predict new-onset MetS during follow-up [102]. The 
presence of MetS was associated with low-normal FT4 levels in Korean men and women [37], and in 
post-menopausal women [38]. In addition, more severe insulin resistance, as determined by homeostasis 
model assessment, was associated with low-normal FT4 levels in the PREVEND cohort [36] and a 
Mexican population-based study [39]. However, neither the prevalence of MetS, nor its individual 
components, were related to SCH in the Mexican study [39]. Additionally, SHH was found to predict 
the presence of MetS and more severe insulin resistance only in subjects with concomitant NAFLD [23]. 
A considerable number of studies have dealt with the relationship of thyroid function with obesity, as 
reviewed elsewhere [103]. Thyroid hormones increase resting energy expenditure [104], which generally 
leads to weight loss in overt hyperthyroidism, but the increase in body weight in overt hypothyroidism 
seems to be mainly due to fluid retention [103]. Nonetheless, small differences in thyroid function even 
within the normal range are likely to be relevant for obesity, as judged by a positive association of BMI 
with the TSH level and an inverse association with FT4, as well as by a higher prevalence of obesity in 
a community-dwelling study among adults from Denmark [105]. Likewise, a positive association of BMI 
and waist circumference with TSH was observed in adult men and women participating in the National 
Health and Nutrition Examination Survey [106]. On the other hand, the hypothalamic-pituitary-thyroid axis 
is probably activated in obesity [103], which could in part be attributable to interactions with adipokines, 
such as leptin [107]. Indeed, TSH, as well as FT4 and FT3 levels, may all be higher in obese children [108]. 
Hypothyroidism leads to insulin resistance in striated muscle and adipose tissue, which may be due at 
least in part to decreased translocation of GLUT4 to the cell membrane, impairing glucose transport [56,109]. 
Additionally, insulin clearance may be diminished in hypothyroidism coinciding with higher levels 
of counter-regulatory hormones, i.e., cortisol, glucagon, growth hormone and adrenalin [110]. Thus, 
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despite increased gluconeogenesis in hyperthyroidism, and enhanced glucose-stimulated insulin secretion in 
overt hypothyroidism and SCH, plasma glucose levels tend to be higher in hypothyroidism [111,112]. 
Accordingly, a low-normal FT4 may relate to somewhat higher fasting plasma glucose levels [36]. 
Overt thyroid dysfunction is associated with profound effects on cardiovascular hemodynamics and 
cardiac function [1]. Triiodothyronine increases thermogenesis and decreases systemic vascular 
resistance, which in turn decreases effective arterial filling volume, stimulates renal reabsorption of 
sodium and increases blood volume [1]. An increased blood volume together with direct effects of 
triiodothyronine on the heart enhances cardiac inotropy and chronotropy, thereby stimulating cardiac 
output. In overt hypothyroidism, systemic vascular resistance is increased, whereas the heart rate and 
the ejection fraction are decreased, but the systemic hemodynamic effects of hypothyroidism are less 
outspoken than those accompanying hyperthyroidism [1]. SCH is associated with minor elevations in 
systolic and diastolic blood pressure. A meta-analysis comprising seven cross-sectional studies 
documented a small increase in systolic blood pressure of 1.89 mmHg and in diastolic blood pressure of 
0.75 mmHg in SCH [113]. Accordingly, effects of low-normal thyroid function on systemic blood 
pressure are probably minimal. In the Busselton Health study and in the PREVEND study, blood 
pressure was not significantly associated with low-normal thyroid function [36,114]. In other surveys, 
positive associations of systolic or diastolic blood pressure with TSH were found [38,39], although 
positive associations of blood pressure with FT4 levels have also been reported [37]. 
4. Subclinical Hypothyroidism, Low-Normal Thyroid Function and Non-Alcohol Fatty Liver Disease 
NAFLD includes a broad spectrum of pathology ranging from simple steatosis to non-alcoholic 
steatohepatitis (NASH), fibrosis and cirrhosis [115,116]. NAFLD also predisposes to hepatocellular 
carcinoma. NAFLD has become a leading cause of liver disease worldwide, and it is estimated that 
NAFLD occurs in more than 30% of American and European adults [117–120]. NAFLD is considered 
to reflect the hepatic component of MetS, since there is a strong association with insulin resistance, 
hypertension, obesity and dyslipidemia [121]. Accumulating evidence supports an association between 
NAFLD and increased risk of CVD [122,123]. 
Thyroid hormones play a key role in the hepatic lipid metabolism by a variety of mechanisms  
(see 2.2). Conversely, hepatic fat accumulation is regarded as the driving force of MetS- and  
T2DM-associated dyslipidemia [61–63]. These metabolic abnormalities may result in elevated plasma 
activity of phospholipid transfer protein, an emerging cardiometabolic risk factor which is intricately 
involved in HDL remodeling, triglyceride metabolism and anti-oxidant status [124–126]. Thyroid 
hormones do not only increase hepatic lipogenesis, but also enhance fatty acid β-oxidation [44,45,127]. 
Agonists of thyroid hormone receptor β, i.e., the subunit which is naturally expressed in hepatocytes, 
improve hepatic fat accumulation in animal studies [128]. Although increased fatty acid β-oxidation is 
anticipated to attenuate hepatic fat accumulation, this process may at the same time result in excessive 
mitochondrial production of reactive oxygen species. Among other mechanisms, thyroid hormones are 
likely to affect hepatic lipid accumulation and the subsequent development of fibrosis via an effect on 
the regulation of adiponectin which stimulates fatty acid oxidation and inhibits de novo  
lipogenesis [60,129,130]. Interestingly, genetic factors, such as variation in patatin-like phospholipase 
domain containing 3 (PNPLA3), which encodes a lipid droplet-associated, carbohydrate-regulated 
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triglyceride hydrolase, probably play an important role in the development of NAFLD [131,132]. Little 
is currently known about gene-gene and gene-environment interactions that may be implicated in its  
pathogenesis [131].  
A considerable number of studies have demonstrated an association between hypothyroidism and 
NAFLD. Subjects with hypothyroidism are about 1.5 to 2 times more likely to have biopsy-proven or 
ultrasonography confirmed NAFLD [59,133]. NAFLD is associated with hypothyroidism in a dose-
dependent manner, independent of metabolic risk factors (SCH: odds ratio 1.36; overt hypothyroidism: odds 
ratio 1.71) [133]. Likewise, serum alanine aminotransferase (ALT) elevations, a surrogate marker of 
NAFLD [123], are associated with a higher TSH level across the spectrum of hypo- to hyperthyroidism [134]. 
In line, a systematic review suggested that NAFLD is related to hypothyroidism [60], although associations 
of NAFLD with thyroid function abnormalities have not been unequivocally reported [135].  
There are a few studies which investigated the association of NAFLD with variations in thyroid 
function within the euthyroid range. Among 878 elderly Chinese subjects, NAFLD (prevalence 25.9%, 
determined by ultrasonography) was independently associated with lower FT4 levels [136]. Likewise, 
NAFLD (prevalence 26.5%, determined by ultrasonography) was associated with high-normal TSH and 
low-normal FT4 levels in another study in 739 Chinese subjects when taking account of metabolic risk 
factors [137]. In a large German study, an association of NAFLD (based on ultrasonorography and ALT 
elevations) with lower FT4, but not with lower FT3 or higher TSH levels was documented [138]. In 
another community-based Chinese survey study among euthyroid 1322 adults, TSH levels were higher 
in female subjects with NAFLD, but this difference disappeared after adjustment for adiposity [139]. In a 
small study in euthyroid subjects with biopsy-proven NAFLD, NASH was predicted by high-normal TSH 
levels [140]. In apparent disagreement with the above mentioned reports [133,134,136–140], NAFLD 
(determined by ultrasonorography) was more prevalent in subjects with low TSH level among 832 
Iranian subjects, most of them being euthyroid, although FT4 levels were not different between subject 
with and without NAFLD [141]. In a study comprising 82 euthyroid subjects with and without MetS, 
we recently found that low-normal thyroid function, as judged from a higher TSH level within the normal 
range, may attenuate ALT elevations in the context of MetS and insulin resistance [142]. Taken together, 
it is plausible that NAFLD is associated with overt and subclinical hypothyroidism, but it is currently 
uncertain whether the same holds true for variations in thyroid function within the low normal range. 
Methodological issues with respect to the assessment of NAFLD, as well as ethnic differences in 
NAFLD susceptibility could in part explain the discrepancies.  
5. Low-Normal Thyroid Function and Bilirubin  
Bilirubin, the end product of heme catabolism, is a strong natural anti-oxidant, due to its ability to 
scavenge peroxyl radicals, a process which diminishes oxidative modification of LDL [143,144]. 
Besides anti-oxidant activity, bilirubin inhibits platelet activation, is able to attenuate expression of 
cellular adhesion molecules and has pro-atherogenic effects on lipoprotein metabolism [145–148]. 
Hence, the concept is emerging that bilirubin may play a role in the pathogenesis of cardiometabolic 
disorders characterized by increased oxidative stress and low-grade chronic inflammation [148,149]. In 
agreement, low circulating bilirubin levels relate to increased high sensitive C-reactive protein, as well 
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as to serum amyloid A levels [150–152]. Low serum bilirubin probably attenuates the development of 
atherosclerotic manifestations [153–158], even independent from conventional risk factors [159].  
The generation of bilirubin from heme involves conversion to biliverdin by the enzyme, heme 
oxygenase (HO), followed by reduction to unconjugated bilirubin by biliverdin reductase [144,148–160]. 
After diffusion into the circulation, where bilirubin is bound to albumin, bilirubin is taken up by 
hepatocytes, conjugated by uridine 5′-diphospho-glucuronosyltransferase (UGT1A1), and excreted into 
the bile. Two HO genes have been documented, of which the HO-1 enzyme is inducible, whereas HO-2 
is constitutively expressed [149,161].  
At least two pathways are involved in the regulation of bilirubin metabolism by thyroid hormones. 
First, HO-1 expression is induced by triiodothyronine, as documented by several in vitro  
models [162,163]. Second, bilirubin conjugation is controlled by thyroid hormone which decreases 
UGT1A1 enzymatic activity [164,165]. Since effects of thyroid hormone on these pathways are 
anticipated to increase circulating bilirubin, it is plausible to postulate that low-normal thyroid function 
may relate to lower bilirubin levels. To determine the extent to which low-normal thyroid function may 
influence serum bilirubin, we have recently carried out two studies among euthyroid subjects with 
varying degrees of glucose tolerance [166,167]. We first compared relationships of serum total bilirubin 
with thyroid function between non-diabetic and T2DM subjects [166], reasoning that alterations in 
bilirubin metabolism could affect enhanced oxidative stress which is a prominent feature of chronic 
hyperglycemia [168]. Serum bilirubin was related positively with FT4 in T2DM subjects, but not 
significantly in non-diabetic subjects [166]. To further delineate the impact of insulin resistance on the 
relationship of serum bilirubin with thyroid function, we explored whether more severe insulin resistance 
(homeostasis model assessment) modified the relationship of bilirubin with TSH in a large group of  
non-diabetic subjects [167]. In the whole population, there was a modest positive relationship of bilirubin 
with FT4. This relationship was more prominent in more insulin resistant individuals [167]. These results 
are consistent with the hypothesis that low-normal thyroid function may contribute to lower circulating 
bilirubin levels, and suggest that this effect is more outspoken in the context of chronic hyperglycemia 
and insulin resistance. Thus, it appears that low-normal thyroid function may affect bilirubin metabolism, 
thereby providing a potentially relevant mechanism contributing to enhanced oxidative stress and  
low-grade chronic inflammation with putative adverse consequences for atherosclerosis susceptibility.  
6. Conclusions 
In this review, we have delineated accumulating evidence which supports the concept that low-normal 
thyroid function, i.e., either higher TSH or lower FT4 levels within the euthyroid range, may play a 
pathogenetic role in the development of atherosclerotic cardiovascular disease. As yet, the extent to 
which low-normal thyroid function impacts on cardiovascular outcome is still unclear. It is also unknown 
whether possible adverse effects of low-normal thyroid function on cardiovascular outcome may be 
particularly relevant for specific populations, such as younger people and subjects at high cardiovascular 
risk. Alike subclinical hypothyroidism, low-normal thyroid function probably relates to modest increases 
in plasma total cholesterol, LDL cholesterol and triglycerides, but effects on HDL cholesterol are 
inconsistent. Additionally, low-normal thyroid function may be associated with insulin resistance and 
with other components of the metabolic syndrome, i.e., (central) obesity and plasma glucose. Effects of 
 
Nutrients 2015, 7 1366 
 
low-normal thyroid function on systemic blood pressure are minimal. Whereas the prevalence of 
NAFLD is increased in SCH, inconsistent effects of low-normal thyroid function on (markers of) 
NAFLD have been reported so far. Of further note, it has been recently demonstrated that low-normal 
thyroid function may promote plasma cholesteryl ester transfer protein-mediated cholesteryl ester transfer, 
and results in impaired ability of HDL to inhibit oxidative modification of LDL, both reflecting pro-
atherogenic alterations in lipoprotein-associated processes. Low-normal thyroid function also relates to 
lower levels of bilirubin, which has strong anti-oxidative and anti-inflammatory properties. Remarkably, 
all these effects of low-normal thyroid functional status appear to be more outspoken in the context of 
chronic hyperglycemia and/or insulin resistance, which raises the possibility that diabetic subjects are 
particularly susceptible to consequences of low-normal thyroid function. Collectively, these findings 
agree with the concept that low-normal thyroid function may adversely affect several processes which 
conceivably contribute to the pathogenesis of atherosclerotic cardiovascular disease beyond effects on 
conventional lipoprotein measures. 
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